RRM2 Enhances MYCN-driven Neuroblastoma Formation and Acts As a Synergistic Target with CHK1 Inhibition

High-risk neuroblastoma, a pediatric tumor originating from the sympathetic nervous system, has a low mutation load but highly recurrent somatic DNA copy number variants. Previously, segmental gains and/or amplifications allowed identification of drivers for neuroblastoma development. Using this approach, combined with gene dosage impact on expression and survival, we identified ribonucleotide reductase subunit M2 (RRM2) as a candidate dependency factor further supported by growth inhibition upon in vitro knockdown and accelerated tumor formation in a neuroblastoma zebrafish model coexpressing human RRM2 with MYCN. Forced RRM2 induction alleviates excessive replicative stress induced by CHK1 inhibition, while high RRM2 expression in human neuroblastomas correlates with high CHK1 activity. MYCN-driven zebrafish tumors with RRM2 co-overexpression exhibit differentially expressed DNA repair genes in keeping with enhanced ATR-CHK1 signaling activity. In vitro, RRM2 inhibition enhances intrinsic replication stress checkpoint addiction. Last, combinatorial RRM2-CHK1 inhibition acts synergistic in high-risk neuroblastoma cell lines and patient-derived xenograft models, illustrating the therapeutic potential.

Citing Articles

Synergistic machine learning models utilizing ferroptosis-related genes for improved neuroblastoma outcome prediction.

Cheng J, Dong X, Yang Y, Qin X, Zhou X, Zhang D Transl Pediatr. 2025; 13(12):2164-2182.

PMID: 39822999 PMC: 11732634. DOI: 10.21037/tp-24-323.

Ribonucleotide reductase small subunit M2 promotes the proliferation of esophageal squamous cell carcinoma cells HuR-mediated mRNA stabilization.

Zhang J, Wu Q, Xie Y, Li F, Wei H, Jiang Y Acta Pharm Sin B. 2024; 14(10):4329-4344.

PMID: 39525580 PMC: 11544187. DOI: 10.1016/j.apsb.2024.07.022.

Single cell sequencing of zebrafish kidney marrows reveals AHR2-dependent endogenous regulation of hematopoiesis.

Dasgupta S, Goodale B, Tanguay R bioRxiv. 2024; .

PMID: 38712290 PMC: 11071399. DOI: 10.1101/2024.04.23.590755.

A structure-based designed small molecule depletes hRpn13 and a select group of KEN box proteins.

Lu X, Chandravanshi M, Sabbasani V, Gaikwad S, Hughitt V, Gyabaah-Kessie N Nat Commun. 2024; 15(1):2485.

PMID: 38509117 PMC: 10954691. DOI: 10.1038/s41467-024-46644-7.

Preclinical exploration of the DNA damage response pathway using the interactive neuroblastoma cell line explorer CLEAN.

Gabre J, Merseburger P, Claeys A, Siaw J, Bekaert S, Speleman F NAR Cancer. 2024; 6(1):zcad062.

PMID: 38213997 PMC: 10782898. DOI: 10.1093/narcan/zcad062.

References

Blosser W, Dempsey J, McNulty A, Rao X, Ebert P, Lowery C . A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib. Oncotarget. 2020; 11(3):216-236. PMC: 6980627. DOI: 10.18632/oncotarget.27400. View

Pfister S, Markkanen E, Jiang Y, Sarkar S, Woodcock M, Orlando G . Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation. Cancer Cell. 2015; 28(5):557-568. PMC: 4643307. DOI: 10.1016/j.ccell.2015.09.015. View

Saldivar J, Cortez D, Cimprich K . The essential kinase ATR: ensuring faithful duplication of a challenging genome. Nat Rev Mol Cell Biol. 2017; 18(10):622-636. PMC: 5796526. DOI: 10.1038/nrm.2017.67. View

Liang M, Zhao T, Ma L, Guo Y . CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation. Oncol Rep. 2017; 39(3):1322-1330. DOI: 10.3892/or.2017.6168. View

Zhu S, Lee J, Guo F, Shin J, Perez-Atayde A, Kutok J . Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell. 2012; 21(3):362-73. PMC: 3315700. DOI: 10.1016/j.ccr.2012.02.010. View

Zhao P, Sasaki T, Gilbert D . High-resolution Repli-Seq defines the temporal choreography of initiation, elongation and termination of replication in mammalian cells. Genome Biol. 2020; 21(1):76. PMC: 7092589. DOI: 10.1186/s13059-020-01983-8. View

Kotsantis P, Silva L, Irmscher S, Jones R, Folkes L, Gromak N . Increased global transcription activity as a mechanism of replication stress in cancer. Nat Commun. 2016; 7:13087. PMC: 5062618. DOI: 10.1038/ncomms13087. View

Cohen M, Zhang S, Sengupta S, Ma H, Bell G, Horton B . Formation of Human Neuroblastoma in Mouse-Human Neural Crest Chimeras. Cell Stem Cell. 2020; 26(4):579-592.e6. PMC: 7663823. DOI: 10.1016/j.stem.2020.02.001. View

Morimoto Y, Takada K, Takeuchi O, Takagi A, Watanabe K, Hirohara M . Prexasertib increases the sensitivity of pancreatic cancer cells to gemcitabine and S‑1. Oncol Rep. 2019; 43(2):689-699. DOI: 10.3892/or.2019.7421. View

10.

Ohmura S, Marchetto A, Orth M, Li J, Jabar S, Ranft A . Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma. Mol Cancer. 2021; 20(1):97. PMC: 8314608. DOI: 10.1186/s12943-021-01393-9. View

11.

Ishida S, Huang E, Zuzan H, Spang R, Leone G, West M . Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol. 2001; 21(14):4684-99. PMC: 87143. DOI: 10.1128/MCB.21.14.4684-4699.2001. View

12.

Liu Y, Li Y, Wang X, Liu F, Gao P, Quinn M . Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma. Cancer Res. 2017; 77(18):5068-5076. PMC: 5600859. DOI: 10.1158/0008-5472.CAN-17-0567. View

13.

Mosse Y, Laudenslager M, Longo L, Cole K, Wood A, Attiyeh E . Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008; 455(7215):930-5. PMC: 2672043. DOI: 10.1038/nature07261. View

14.

Ung C, Guo F, Zhang X, Zhu Z, Zhu S . Mosaic zebrafish transgenesis for functional genomic analysis of candidate cooperative genes in tumor pathogenesis. J Vis Exp. 2015; (97). PMC: 4401404. DOI: 10.3791/52567. View

15.

Slaats G, Giles R . Are renal ciliopathies (replication) stressed out?. Trends Cell Biol. 2015; 25(6):317-9. DOI: 10.1016/j.tcb.2015.03.005. View

16.

Decaesteker B, Durinck K, Van Roy N, De Wilde B, Van Neste C, Van Haver S . From DNA Copy Number Gains and Tumor Dependencies to Novel Therapeutic Targets for High-Risk Neuroblastoma. J Pers Med. 2021; 11(12). PMC: 8707517. DOI: 10.3390/jpm11121286. View

17.

Herold S, Kalb J, Buchel G, Ade C, Baluapuri A, Xu J . Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymerase. Nature. 2019; 567(7749):545-549. PMC: 7611299. DOI: 10.1038/s41586-019-1030-9. View

18.

Tan J, Fogley R, Flynn R, Ablain J, Yang S, Saint-Andre V . Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma. Mol Cell. 2016; 62(1):34-46. PMC: 4836061. DOI: 10.1016/j.molcel.2016.03.013. View

19.

Aird K, Iwasaki O, Kossenkov A, Tanizawa H, Fatkhutdinov N, Bitler B . HMGB2 orchestrates the chromatin landscape of senescence-associated secretory phenotype gene loci. J Cell Biol. 2016; 215(3):325-334. PMC: 5100296. DOI: 10.1083/jcb.201608026. View

20.

Depuydt P, Koster J, Boeva V, Hocking T, Speleman F, Schleiermacher G . Meta-mining of copy number profiles of high-risk neuroblastoma tumors. Sci Data. 2018; 5:180240. PMC: 6207068. DOI: 10.1038/sdata.2018.240. View